Viekira Pak Lawsuit

Viekira Pak, a direct-acting antiviral medication indicated to treat Hepatitis C, has ben associated with liver injury, liver failure and reactivation of the Hepatitis B virus in co-infected patients. Filing a Viekira Pak lawsuit may be an option for individuals who suffered these life-threatening complications while using this medication.

Viekira Pak Legal Reviews

The nationwide law firm of Bernstein Liebhard LLP is evaluating potential Viekira Pak lawsuits involving:

  • Serious liver injuries
  • Liver failure
  • Reactivation of Hepatitis B virus

If you or a loved one experienced any of these issues while undergoing treatment with Viekira Pak, please call (888) 994-5118 to contact our attorneys today.

Viekira Pak FDA Warnings

Viekira Pak s an oral, direct-acting antiviral approved to treat adults with genotype 1 chronic Hepatitis C. Its active ingredients include three direct acting antivirals, paritaprevir, ritonavir, and  ombitasvir, as well as an antiviral called dasabuvir. Viekira Pak is sometimes used in conjunction with another Hepatitis C antiviral called ribavirin.

About 90% of patients taking Viekira Pak will be cured of Hepatitis C. However, the drug is not without risk. Since granting Viekira Pak approval in December 2014, the U.S. Food & Drug Administration (FDA) has issued a number of safety alerts for it and other direct-acting antivirals:

  • October 2015: The FDA warned that Viekira Pak and Technivie could cause serious liver injury, including liver failure. The agency acted after a review identified 26 cases of hepatic decompensation and liver failure in patients with underlying liver cirrhosis who were taking these medicines. In most cases, the liver injury occurred within 1 to 4 weeks of starting treatment. The most serious outcomes, which resulted in liver transplantation or death, were mostly seen in patients taking Viekira Pak who had evidence of advanced cirrhosis even before treatment was initiated. Patients taking Viekira Pak or Technivie should contact their health care professional immediately if they develop fatigue, weakness, loss of appetite, nausea and vomiting, yellow eyes or skin, or light-colored stools, as these may be signs of liver injury.
  • October 2017: The FDA ordered the manufacturers of Viekira Pak and other direct-acting antivirals to add a Black Box Warning regarding a potential for reactivation of the Hepatitis B virus in co-infected patients. According to the agency, 24 cases of Hepatitis B reactivation had been reported in relation to direct-acting antivirals from November 22, 2013 to July 18, 2016. Two patients died and one required a liver transplant. Viekira Pak patients co-infected with Hepatitis C and B should contact their healthcare provider if they experience any signs or symptoms of Hepatitis B reactivation, including fatigue; weakness; loss of appetite; nausea and vomiting; or yellowing of the eyes or skin.

Our Attorneys Can Help

Viekira Pak patients who suffered serious liver injuries, liver failure or Hepatitis B virus reactivation may be entitled to compensation for injury-related damages, including:

  • Medical bills
  • Lost wages
  • Disability
  • Emotional distress
  • Wrongful death

Our attorneys are standing by to help patients and their families obtain the compensation they deserve. To learn more about filing a Viekira Pak lawsuit, please call (888) 994-5118 to arrange for a free, no-obligation review of your case.

  1. FDA (2015) “FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie”
  2. FDA (2016) “FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C:
Last Modified: January 31, 2017

Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.


Follow Us on Google+ on Facebook on LinkedIn on Twitter on YouTube on Pinterest

Skip to content